Status:
COMPLETED
Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamics and pharmacokinetics of single doses of insulin detemir and insulin NPH in subjects with type 2 diabetes...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Subjects treated with insulin for minimum 3 months
- Duration of diabetes for at least 12 months
- Body Mass Index (BMI) below 30 kg/m\^2
- HbA1c maximum 10% based on analysis from central laboratory
Exclusion
- Current treatment with insulin above 1.2 U/kg/day
- Current treatment with insulin glargine
- Current treatment with drugs known to interfere with glucose metabolism
- Current treatment with oral antidiabetic drugs
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2003
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT01497561
Start Date
March 1 2003
End Date
June 1 2003
Last Update
January 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Graz, Germany, 8036